SEC Form 4 · accession 0001005201-18-000027
Assertio Therapeutics, Inc · ASRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William McKee
Director
Period of report
Dec 14, 2018
Accepted (ET)
Dec 17, 2018 · 10:53 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005201
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Dec 14, 2018 | S | 10,000 | $4.0693 | D | 9,512 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2018.
- F2The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on December 14, 2018 at prices ranging from $3.99 to $4.16 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price.